Pd1 and vegfr2 dual-binding agents
AssigneeOttimo Pharma Limited
InventorWilliam James Jonathan FINLAY
Life of this patent
Estimating the term…
Abstract
Provided herein are antibody molecules that bind specifically to Programmed cell death 1 (PD1) and Vascular endothelial growth factor receptor 2 (VEGFR2), related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.
Claims21
-30. (canceled)
An isolated nucleic acid molecule encoding a heavy chain variable (VH) region of an antibody or antigen-binding portion thereof that specifically binds to PD1 and VEGFR2, wherein the VH region comprises:
- (a) a HCDR1 having an amino acid sequence of SEQ ID NO:
- 1;
- (b) a HCDR2 having an amino sequence of SEQ ID NO:
- 42;
- and
- (c) a HCDR3 having an amino acid sequence of SEQ ID NO:
- 3.
An isolated nucleic acid molecule encoding a light chain variable (VL) region of an antibody or antigen-binding portion thereof that specifically binds to PD1 and VEGFR2, wherein the VL region comprises:
- (a) a LCDR1 having an amino acid sequence of SEQ ID NO:
- 39;
- (b) a LCDR2 having an amino sequence of SEQ ID NO:
- 40;
- and
- (c) a LCDR3 having an amino acid sequence of SEQ ID NO:
- 11.
A nucleic acid composition comprising a first nucleic acid encoding a VH region comprising the amino acid sequence of SEQ ID NO:
- 49, and a second nucleic acid encoding a VL region comprising the amino acid sequence of SEQ ID NO:
- 45.
A nucleic acid composition comprising a first nucleic acid encoding a heavy chain of an antibody molecule and a second nucleic acid encoding a light chain of an antibody molecule, wherein
- (a) the heavy chain comprises a VH region having an amino acid sequence of SEQ ID NO:
- 49, and an IgG1 immunoglobulin constant region having an amino acid sequence of SEQ ID NO:
- 28, and
- (b) the light chain comprises a VL region having an amino acid sequence of SEQ ID NO:
- 45, and a human kappa light chain constant region.
Dependencies are inferred from the claim text.